Get the Stockscreener App
1.30
1.56%
0.02
Telomir Pharmaceuticals Inc stock is traded at $1.30, with a volume of 128.28K.
It is up +1.56% in the last 24 hours and down -10.34% over the past month.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
See More
Previous Close:
$1.28
Open:
$1.26
24h Volume:
128.28K
Relative Volume:
0.99
Market Cap:
$89.41M
Revenue:
-
Net Income/Loss:
$-9.22M
P/E Ratio:
-4.4566
EPS:
-0.2917
Net Cash Flow:
$-4.60M
1W Performance:
+0.78%
1M Performance:
-10.34%
6M Performance:
-2.99%
1Y Performance:
-38.10%
1-Day Range:
$1.25
$1.31
1-Week Range:
$1.25
$1.31
52-Week Range:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.30 | 88.03M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Significant EPS Miss Amid Pre-Clinical Stage Operations - Newser
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue ChallengesCFO Commentary Report - thelegaladvocate.com
TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) - ChartMill
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesEarnings Growth Forecast - Newser
Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) director resets 25K stock options terms - Stock Titan
Telomir Pharmaceuticals Q4 2025 Earnings: Wider-than-Expected Loss as Revenue Remains AbsentRising Community Picks - Newser
Telomir Pharmaceuticals (TELO) Stock Analysis: -4.96% Down — Bearish Signals to Watch 2026-05-21Smart Money Flow Stocks - Newser
Telomir Pharmaceuticals (TELO) Q4 2025 Miss: What Went WrongQuarterly Financial Update - thelegaladvocate.com
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Improves Survival and Liver Outcomes in Wilson’s Disease Model - Minichart
Telomir Pharmaceuticals publishes peer-reviewed study on Telomir-Zn for Wilson disease - Traders Union
Telomir-Zn Preclinical Data Published in Wilson’s Disease - TipRanks
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease - ACCESS Newswire
Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO) - Stock Titan
Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Pharmaceuticals (TELO) Q4 2025 Disappoints — EPS $-0.28 Below $-0.07 ViewsEBITDA Margin Trends - Newser
Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
Telomir (NASDAQ: TELO) closes TELI deal amid Q1 loss and cash risk - Stock Titan
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn - TipRanks
Telomir Pharmaceuticals (TELO) wins FDA IND clearance for Telomir‑Zn Phase 1/2 cancer trial - Stock Titan
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - Corsicana Daily Sun
FDA IND clearance puts Telomir's TNBC drug into first human testing - Stock Titan
Telomir shares surge after breakthrough tumor suppressor gene reactivation data - MSN
Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition - Stock Titan
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1 - citybuzz -
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com - Investing.com India
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals and Files Form 8-K with Nasdaq Listing - Minichart
Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights - TipRanks
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition - Investing.com
Telomir completes acquisition of TELI Pharmaceuticals By Investing.com - Investing.com UK
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares - TradingView
Telomir (NASDAQ: TELO) closes TELI acquisition, issues 34,389,710 shares and adds funding - Stock Titan
Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan
TELO Telomir Pharmaceuticals gains slightly even as Q4 2025 EPS lands far below analyst consensus estimates.Community Sell Signals - Xã Thanh Hà
Telomir Pharmaceuticals unveils preclinical data for Telomir-1 at AACR Annual Meeting - Traders Union
Telomir Pharmaceuticals (TELO) Stock: Is It a Compelling Buy (Tumbles Hard) 2026-04-20Analyst Consensus - Xã Vĩnh Công
Telomir Pharmaceuticals (TELO) Stock: Why You Should Hold It (+2.29%) 2026-04-15Expert Entry Points - Xã Thanh Hà
Is Telomir Pharmaceuticals (TELO) Stock Lagging the Market | Price at $1.25, Up 2.46%IV Spike - newsline.com
Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Is Telomir Pharmaceuticals (TELO) Stock Growing Now | Price at $1.30, Up 2.36%Inverse ETF Flow - thelegaladvocate.com
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):